Chaperone-mediated autophagy targets IFNAR1 for lysosomal degradation in free fatty acid treated HCV cell culture

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Kurt, Ramazan ^a   Chandra, Partha K ^a   Aboulnasr, Fatma ^a   Panigrahi, Rajesh ^a   Ferraris, Pauline ^a   Aydin, Yucel ^a   Reiss, Krzysztof ^b   Wu, Tong ^a   Balart, Luis A ^a   Dash, Srikanta ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; FAT DROPLET; FATTY ACID; GAMMA INTERFERON; HEAT SHOCK COGNATE PROTEIN 70; INTERFERON ALPHA RECEPTOR 1; JANUS KINASE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2A; STAT PROTEIN; UNCLASSIFIED DRUG; ALPHA BETA INTERFERON RECEPTOR; ANTIVIRUS AGENT; IFNAR1 PROTEIN, HUMAN; INTERFERON; PROTEIN BINDING;

ARTICLE; CHAPERONE-MEDIATED AUTOPHAGY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FATTY LIVER; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; LIPID STORAGE; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; VIRAL CLEARANCE; VIRUS INHIBITION; VIRUS REPLICATION; WESTERN BLOTTING; AUTOPHAGY; CELL CULTURE; CELL LINE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HEPACIVIRUS; LYSOSOME; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; VIROLOGY;

HEPATITIS C VIRUS; RENILLA LUCIFERASE;

ANTIVIRAL AGENTS; AUTOPHAGY; CELL LINE; CELLS, CULTURED; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; GENE EXPRESSION; HEPACIVIRUS; HUMANS; INTERFERON TYPE I; INTERFERON-GAMMA; JANUS KINASES; LYSOSOMES; PHOSPHORYLATION; PROTEIN BINDING; PROTEOLYSIS; RECEPTOR, INTERFERON ALPHA-BETA; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; VIRUS REPLICATION;

EID: 84930623937     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125962     Document Type: Article

References (48)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29 Suppl 1: 74-81. doi: 10.1111/j.1478-3231.2008.01934.x PMID: 19207969
2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2006; 5:558-567.
3. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases. Hepatology. 2011, 54(4): 1433-44 doi: 10.1002/hep.24641 PMID: 21898493
4. Aronsohn A, Jensen D. Interferon-combination strategies for the treatment of chronic hepatitis C. Semin Liver Dis. 2014; 34:30-36. doi: 10.1055/s-0034-1371008 PMID: 24782256
5. Forestier N, Zeuzem S. Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders. Liver Int. 2012; 32:44-50. doi: 10.1111/j.1478-3231.2011.02720.x PMID: 22212571
6. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Eng. J Med. 2011; 364:2417-2428. doi: 10.1056/NEJMoa1013086 PMID: 21696308
7. Asselah T. Triple therapy with boceprevir or telaprevir for prior HCV non-responders. Bext Practice and Research Clinical Gastroenterology, 2012; 26:455-462. doi: 10.1016/j.bpg.2012.09.003 PMID: 23199504
8. Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M et al. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver International. 2010; 30: 1259-1269. doi: 10.1111/j.1478-3231.2010.02283.x PMID: 20633102
9. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001; 21:3-16. PMID: 11296695
10. Burt AD, Mutton A, Day CP. Diagnosis and interpretation of steatosis and steatohepatitis. Semin Diagn Pathol.1998; 15: 246-258. PMID: 9845426
11. Syed GH, Amako Y, Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinolo Metab. 2010; 21:33-40. doi: 10.1016/j.tem.2009.07.005 PMID: 19854061
12. Herket E, Ott M. Unique ties between hepatitis C virus replication and intracellular lipids. Trends Endocrinol Metab. 2011; 22: 241-248. doi: 10.1016/j.tem.2011.03.004 PMID: 21497514
13. García-Mediavilla MV, Pisonero-Vaquero S, Lima-Cabello E, Benedicto I, Majano PL, Jorquera F, et al. Liver X receptor alpha mediated regulation of lipogenesis by core and NS5A proteins contributes to HCV-induced liver steatosis and HCV replication. Lab Investigation. 2012; 92:1191-1202. doi: 10.1038/labinvest.2012.88 PMID: 22641099
14. Negro F. Abnormalities of lipid metabolisms in hepatitis C virus infection. Gut. 2010; 59:1279-1287. doi: 10.1136/gut.2009.192732 PMID: 20660700
15. Lambart JE, Bain VG, Ryan EA, Thomson ABR, Clandinin MT. Elevated lipogenesis and diminished cholesterol synthesis in patients with hepatitis C viral infection compared to healthy humans. Hepatology. 2013; 57:1697-1704. doi: 10.1002/hep.25990 PMID: 23417775
16. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus and alcohol. Hepatology. 2002; 36: 729-736. PMID: 12198667
17. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, et al. Effect of treatment with peginterferon or interferon alpha-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 2003; 38:75-85. PMID: 12829989
18. Puri P, Sanyal AJ. Role of obesity, insulin resistance and steatosis in hepatitis C virus infection. Clin Liver Dis. 2006; 10:703-819.
19. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001; 33:1358-1364. PMID: 11391523
20. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponsive to antiviral treatment in chronic hepatitis C. Hepatology. 2003; 38:639-644. PMID: 12939590
21. Restivo L, Zampino R, Guerrera B, Ruggiero L, Adinolfi LE. Steatosis is the predictor of relapse in HCV genotype 3-but not 2-infected patients treated with 12 weeks of pegylated interferon-alpha 2a plus ribavirin and RVR. J Viral Hepatitis. 2012; 19:346-352. doi: 10.1111/j.1365-2893.2011.01555.x PMID: 22497814
22. Negro F, Clement S. Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C. J Viral Hepatitis. 2009; 16:681-688.
23. Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P et al. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond). 2004; 106:635-643. PMID: 14720121
24. Gunduz F, Aboulnasr FM, Chandra PK, Hazari S, Poat B, Baker DP et al. Free fatty acids induce ER stress and block antiviral activity of interferon alpha against hepatitis C virus in cell culture. Virology Journal. 2012; 9:e143.
25. Liu S, Nelson CA, Xiao L, Lu L, Seth PP, Davis DR et al. Measuring antiviral activity of benzimidazole molecules that alters IRES RNA structure with an infectious hepatitis C virus chimera expressing Renilla luciferase. Antiviral Res, 2011; 89:54-63 doi: 10.1016/j.antiviral.2010.11.004 PMID: 21075143
26. Chandra PK, Bao L, Song K, Aboulnasr FM, Baker DP, Shores N et al. HCV Infection Selectively Impairs Type I but Not Type III IFN Signaling. Am J Pathol, 2014; 184:214-229. doi: 10.1016/j.ajpath.2013.10.005 PMID: 24215913
27. Gomez-Lechon MJ, Donato MT, Martinez-Romero A, Jimenez N, Castell JV, O Conner J-E. A human hepatocellular in vitro model to investigate steotosis. Chem Biol Interact. 2007; 165:106-116. PMID: 17188672
28. Masserdoti C, Bonfanti U, De Lorenzi D, Ottolini N. Use of Oil Red O stain in the cytologic diagnosis of canine liposarcoma. Vet Clin Path. 2006; 35:37-41. PMID: 16511789
29. Henriques CM, Rino J, Nibbs RJ, Graham GJ, Barata JT. IL-7 induces rapid clathrin-mediated internalization and JAK3-dependent degradation of IL-7Ralpha in T cells. Blood. 2010; 115: 3269-3277. doi: 10.1182/blood-2009-10-246876 PMID: 20190194
30. Quintavalle C, Di Costanzo S, Zanca C, Tasset I, Fraldi A, Incoronato M, et al. Phosphorylation-regulated degradation of the tumor-suppressor form of PED by chaperone-mediated autophagy in lung cancer cells. Journal of Cellular Physiology. 2014; 229; 1359-1368. doi: 10.1002/jcp.24569 PMID: 24477641
31. Ling LE, Zafari M, Reardon D, Brickelmeier M, Goelz SE, Benjamin CD. Human type I interferon receptor, IFNAR1 is a heavily glycosylated 120-130kD membrane protein. J Interferon Cytokine Res. 1995; 15:55-61. PMID: 7544230
32. Bao L, Chandra PK, Moroz K, Zhang X, Thung SN, Wu T, Dash S. Impaired autophagy response in human hepatocellular carcinoma. Experimental and Molecular Pathology. 2014; 96:149-154. doi: 10.1016/j.yexmp.2013.12.002 PMID: 24369267
33. Chiang HL, Dice JF. Peptide sequences that target proteins for enhanced degradation during serum withdrawal. J Biol Chem. 1988; 263: 6797-6805. PMID: 3360807
34. Dice J. Peptide sequences that target cytosolic proteins for lysosomal proteolysis. Trends Biochem. 1990; 15:305-309. PMID: 2204156
35. Cuervo A, Dice J. A receptor for selective uptake and degradation of proteins by lysosomes. Science. 1996; 273:501-503. PMID: 8662539
36. Finn PF, Mesires NT, Vine M, Dice JF. Effects of small molecules on chaperone-mediated autophagy. Autophagy. 2005; 1:141-145. PMID: 16874031
37. Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J. Gen. Virol. 1997; 78: 1527-31.
38. Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura Y, et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc. Natl. Acad. Sci. U.S.A. 1997; 94: 1200-5. PMID: 9037030
39. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallée M, et al. The impact of steatosis on disease progression and early sustained treatment response in chronic hepatitis C patients. J Hepatoloy, 2004; 40:484-490.
40. Chandra PK, Gunduz F, Hazari S, Ramazan K, Panigrahi R, Poat B et al. Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis. PLOS ONE, 2014; 9:e108616. doi: 10.1371/journal.pone.0108616 PMID: 25265476
41. Panigrahi R, Chandra PK, Ferraris P, Kurt R, Song K, Garry RF, et al. Persistent Hepatitis C Virus Infection Impairs Ribavirin Antiviral Activity through Clathrin-Mediated Trafficking of Equilibrative Nucleoside Transporter 1. J Virol. 2015; 89: 626-42. doi: 10.1128/JVI.02492-14 PMID: 25339775
42. Abid K, Pazienza V, de Gottardi A, Rubbia-Brandt L, Conne B, Pugnale P, et al. An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. J Hepatol. 2005; 42:744-51. PMID: 15826725
43. Ripoli M, Pazienza V. Impact of HCV genetic differences on pathobiology of disease. Expert Rev Anti Infect Ther. 2011; 9: 747-759. doi: 10.1586/eri.11.94 PMID: 21905784
44. Dickensheets H, Sheikh F, Park O, Gao B, Donnelly RP. Interferon-lambda (IFN-l) induces signal transduction and gene expression in human hepatocytes, but not in lymphocytes or monocytes. J Leukoc Biol. 2013; 93:377-385. doi: 10.1189/jlb.0812395 PMID: 23258595
45. Zhang L, Jilg N, Shao RX, Lin W, Fusco DN, Zhao H, et al. IL-28B inhibits hepatitis C virus replication through the Jak-Stat pathway. J Hepatol. 2011; 55:289-298. doi: 10.1016/j.jhep.2010.11.019 PMID: 21147189
46. Liu J, HuangFu WC, Kumar KG, Qian J, Casey JP, Hamanaka RB, et al. Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylation-dependent degradation of the type I interferon receptor. Cell Host Microbe. 2009; 5:72-83. doi: 10.1016/j.chom.2008.11.008 PMID: 19154989
47. Kumar K, Krolewski JJ, Fuchs SY. Phsophorylation and specific ubiquitination accepter sites are required for ubiquitination of the IFNAR1 subunit of the type I IFN receptor. J Biol Chem, 2004; 279:46614-46620. PMID: 15337770
48. Kumar KG, Tang W, Ravindranath AK, Clark WA, Croze E, Fuchs SY. SCF (HOS) ubiquitin ligase mediates the ligand-induced downregulation of the interferon alpha-receptor. EMBO J. 2003; 22:5480-5490. PMID: 14532120